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Abstract: IgG molecules exert both pro- and antiinflammatory effector functions based on the composi-
tion of the fragment crystallizable (Fc) domain glycan. Sialylated IgG Fc domains have antiinflammatory
properties that are attributed to their ability to increase the activation threshold of innate effector cells
to immune complexes by stimulating the upregulation of the inhibitory Fc￿ receptor IIB (Fc￿RIIB). Here,
we report that IgG Fc sialylation of human monoclonal IgG1 molecules impairs their efficacy to induce
complement-mediated cytotoxicity (CDC). Fc sialylation of a CD20-targeting antibody had no impact
on antibody-dependent cellular cytotoxicity and did not change the affinity of the antibody for acti-
vating Fc￿ receptors. In contrast, the presence of sialic acid abrogated the increased binding of C1q to
Fc-galactosylated IgG1 and resulted in decreased levels of C3b deposition on the cell surface. Similar to
monoclonal antibodies, sialic acid inhibited the increased C1q binding to galactosylated Fc fragments in
human polyclonal IgG. In sera derived from patients with chronic inflammatory demyelinating polyneu-
ropathy, an autoimmune disease of the peripheral nervous system in which humoral immune responses
mediate tissue damage, induction of IgG Fc sialylation was associated with clinical disease remission.
Thus, impairment of CDC represents an Fc￿R-independent mechanism by which Fc-sialylated glycovari-
ants might limit proinflammatory IgG effector functions.
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Introduction
IgG molecules can trigger both pro- and antiinflammatory 
responses mediated by their fragment crystallizable domain 
(Fc). Proinflammatory pathways include the activation of innate 
immune effector cells via cellular receptors specific for the anti-
body constant region (Fcγ receptors, herein referred to as FcγRs) 
and the activation of the complement system. Activation of the 
classical complement pathway via C1q binding to human IgG1 
and IgG3 molecules generates proinflammatory anaphylotox-
ins C3a and C5a, which can trigger innate immune effector cell 
recruitment, and deposition of C3b on target cells enables their 
recognition through C3b receptors expressed on phagocytic, anti-
gen-presenting cells (1, 2). Compared with the aforementioned 
effector functions that establish and maintain tissue inflamma-
tion, our understanding how IgG contributes to the resolution of 
inflammation is still vague.
Recent studies provided evidence that carbohydrates in the 
sugar moiety attached to the IgG Fc domain are essential for IgG 
functionality and its antiinflammatory capacity (3). IgG Fc contains a 
single, highly conserved asparagine 297 (N297) glycosylation site in 
each of the 2 CH2 domains. The glycans are buried within the hydro-
phobic core between the 2 heavy chains and influence Fc structure 
(4, 5). The biantennary core glycan structure, which is composed 
of 2 N-acetylglucosamines (GlcNAc) and 3 mannose residues, can 
be further decorated with fucose, bisecting GlcNAc and terminal 
GlcNAc, galactose, and sialic acid. Genetic or enzymatic removal of 
this sugar moiety results in a loss of both pro- and antiinflammatory 
activities of IgG (1, 6).
Antiinflammatory activities of IgG have been associated with 
the presence of sialic acid, based on observations that patients 
with autoimmune diseases such as rheumatoid arthritis show 
decreased levels of IgG Fc sialylation (7–9) and the finding that 
the antiinflammatory activity of i.v. immunoglobulins (IVIG) 
in various murine models of antibody-mediated autoimmune 
diseases could be recapitulated using sialylated Fc fragments 
derived from IVIG or a human IgG1 recombinant antibody at a 
30-fold lower dose than IVIG (10–12).
The antiinflammatory activity of sialylated IgG Fc has 
been attributed to its ability to induce the production of IL-33 
by myeloid regulatory cells upon binding to the lectin DC–spe-
cific ICAM-3–grabbing nonintegrin receptor DC-SIGN, which, 
in turn, induces expansion of IL-4–producing basophils that 
promote increased expression of the inhibitory Fcγ receptor 
FcγRIIB, thereby increasing the activation threshold of innate 
effector cells to immune complexes (13). More recently, it has 
been demonstrated that IgG Fc sialylation acts as a negative reg-
ulator of B cell proliferation independent of FcγRIIB expression 
(14, 15). Here, we show that Fc sialylation inhibits immediate 
proinflammatory IgG effector functions through impairment of 
complement-mediated cytotoxicity.
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To determine whether the effect of Fc sialylation on CDC is RTX 
specific, we additionally enriched a monoclonal humanized 
IgG1 antibody recognizing myelin oligodendrocyte glycoprotein 
(MOG) and lacking Fc sialylation (hu8-18C5) (21) for sialylated 
species by β1,4GalT and ST6Gal1 treatment. CDC was assessed 
with an oligodendroglial cell line (MO3.13) transduced to express 
human full-length MOG (Figure 3 and ref. 22). Similar to RTX, 
sialylated glycoforms of the MOG-specific hu8-18C5 antibody 
were less efficient in inducing CDC compared with their nonsial-
ic acid-carrying counterparts (Figure 2D). The impaired efficacy 
of sialylated IgG to induce CDC was not reflected by decreased 
antigen-binding affinities (Figure 3, C and D). These data indicate 
that IgG Fc sialylation impairs CDC independently from Fc recep-
tor binding and antigen specificity.
Fc sialylation neutralizes increased C1q binding of Fc-galacto-
sylated IgG. The classical complement pathway is triggered by 
binding of C1q to the Fc domain in antibody/antigen complexes, 
leading to autoactivation of the C1 complex (comprising C1q, C1r, 
and C1s) and activation of complement by cleavage of C4 and C2. 
The resulting C4bC2a convertase cleaves C3, causing the covalent 
coupling of C3b to reactive surfaces such as the cell membrane, 
which culminates in the formation of the membrane attack com-
plex and lysis of the target cell (23).
The binding affinity of C1q for murine IgG has been shown to 
be reduced upon the removal of galactose from the IgG Fc–linked 
glycan (24). To investigate the mechanism by which Fc sialylation 
impacts CDC, we first determined binding affinities and kinetics of 
unmodified and tetra-Fc–sialylated RTX with C1q by surface plas-
mon resonance (SPR) analysis. Compared with unmodified IgG, 
the rate of complex formation was lower for tetra-Fc–sialylated IgG 
(kon = 1.6 compared with 3.9/107 [ms]–1) while the rate of dissociation 
was higher (koff = 0.22 compared with 0.15/s–1), resulting in a 3.7-fold 
increased kD for tetra-Fc–sialylated IgG (kD C1q:tetra-Fc–sialylated IgG = 14; 
kD C1q:unmodified IgG = 3.8) (Figure 4). Next, we generated galactosylated, 
galactosylated and sialylated, and degalactosylated Fc glycovari-
ants of RTX and hu8-18C5 (Figure 5, A and D, and Supplemental 
Figure 2) and tested them for their ability to induce cell-associated 
complement activation. Both antibodies contain the Fc-glycosyl-
ation site at N297 but lack additional fragment antigen binding 
(Fab) glycosylation sites (Supplemental Figure 3).
Results
IgG Fc sialylation impairs complement-dependent cytotoxicity. 
Rituximab (RTX) is a chimeric mouse-human IgG1 monoclonal 
antibody that targets the CD20 antigen, which is expressed on B 
lymphocytes. RTX depletes B cells through a combination of anti-
body-dependent cell-mediated cytotoxicity (ADCC) and comple-
ment-dependent cytotoxicity (CDC) (16). The major Fc glycans of 
commercial RTX are core-fucosylated biantennary complex–type 
oligosaccharides carrying 0–2 galactose moieties buy lacking 
sialic acid (refs. 17, 18, and Figure 1A). A homogeneous, tetra-Fc–
sialylated glycoform (G2SA2) of RTX — i.e., carrying 4 sialic acids 
per Fc fragment (2 sialic acids per Fc glycan [Figure 1A and Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI82695DS1]) — was prepared by the chemo-
enzymatic glycosylation remodeling of commercial RTX (17), and 
the purity and identity of the fully sialylated RTX were confirmed 
by electron spray ionization-liquid chromatography/mass spec-
trometry (ESI-LC/MS) analysis of the light chain and heavy chain 
of the product (Figure 1B). We employed these 2 glycoforms— i.e., 
commercial RTX not carrying sialic acid versus tetra-Fc–sialylated 
RTX — to determine whether IgG Fc sialylation impacts the effi-
cacy of CD20-targeted B cell depletion.
Incubation of natural killer cells (NK cells) with either the 
unmodified or tetra-Fc–sialylated antibody resulted in efficient 
lysis of autologous B cells, and the depleting efficacy was simi-
lar between the 2 glycoforms (Figure 2A). In addition, both gly-
coforms exhibited similar binding affinities for the activating Fc 
receptors FcγRIIIA-158F and FcγRIIIA-158V, which, upon liga-
tion, mediate ADCC (Figure 2B). Binding affinities of both glyco-
forms were also similar for FcγRI and FcγRIIA (Supplemental Fig-
ure 1). In stark contrast, tetra-Fc–sialylated RTX was less efficient 
in inducing CDC in CD20+ Burkitt’s lymphoma Raji and Ramos 
cells (Figure 2C). An alternative approach to achieve Fc sialylation 
is to react an Fc glycan containing substrate molecule with β1,4 
galactosyltransferase-1 (β1,4GalT) and α2,6-sialyltransferase 
(ST6Gal1) enzymes in the presence of the corresponding sugar 
nucleotide substrates, which results in enrichment of mono- and 
bisialylated species (Supplemental Figure 2 and refs. 11, 19, 20). 
As shown in Figure 2D, enzymatic enrichment of RTX for sialylat-
ed glycoforms also resulted in decreased efficacy to induce CDC. 
Figure 1. Characterization of unmodified and tetra-Fc–sialylated RTX. (A) Immunoblotting of RTX and tetra-Fc–sialylated RTX using lectins specific for 
individual glycans (mannose: LCA; terminal galactose: ECL; sialic acid: SNA). (B) Liquid chromatography-mass spectrometry (LC/MS) analysis of the tetra-
Fc–sialylated RTX after reduction to separate the light chain and heavy chain.
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sialylation to block C1q binding translated into decreased levels of 
C3b deposition to the cell surface (Supplemental Figure 4).
To investigate whether these effects can be transferred to 
polyclonal IgG, we purified sialylated Fc from IVIG and obtained 
desialylated Fc (i.e., terminally galactosylated Fc) following neur-
aminidase treatment (Figure 6A). Similar to the monoclonal IgGs 
tested, enrichment of terminally galactosylated Fc resulted in 
Incubation of target cells expressing the cell-surface antigens 
for RTX or hu8-18C5 in the presence of human serum complement 
led to rapid binding of C1q (Figure 5). Fc galactosylation of unmod-
ified antibodies resulted in a markedly increased capacity to bind 
C1q. Subsequent addition of sialic acid abrogated increased C1q 
binding of Fc-galactosylated IgG. Fully tetra-Fc–sialylated RTX 
was largely devoid of C1q binding (Figure 5). The capacity of Fc 
Figure 2. IgG Fc sialylation impairs complement-dependent but not cell-mediated cytotoxicity. (A) RTX and tetra-Fc–sialylated RTX mediated lysis of B cells 
(targets) by autologous NK cells (effectors). Representative experiment and quantification of 3 independent experiments. Statistics were performed by t test. 
(B) Binding of RTX and tetra-Fc–sialylated RTX to CHO cells either untransfected or transfected with the low-affinity (158F) or high-affinity (158V) variant 
of FcγRIIIA. (C) Complement-mediated lysis of the CD20+ Raji cells. Representative experiment and quantification of EC50 of 3 independent experiments. 
Statistics were performed by t test. (D) Complement-mediated lysis of CD20+ Raji cells (left) or MO3.13 MOG cells (right) with RTX and anti-MOG (hu8-18C5) or 
Fc-galactosylated and sialylated variants of the antibodies, representative of 3 independent experiments. 158F, Phenylalanine 158; 158V, Valine 158.
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this trial, disease remission was defined as improvement in clinical 
disease severity after 24 weeks and was observed in 32 of 59 (54%) 
patients treated with IVIG and 12 of 58 (21%) patients who received 
placebo (32). We found that patients with clinical disease remis-
sion during placebo therapy could be distinguished from those with 
stable or worsened disease by the induction of Fc sialylation (Figure 
7A). Changes in Fc galactosylation and fucosylation were similar in 
patients with disease remission compared with stable or worsened 
disease. In patients who received IVIG, we detected an increase of 
total IgG serum levels 2 weeks after the last infusion compared with 
baseline levels (Supplemental Figure 5A), which precluded profiling 
of endogenous IgG in this cohort. We therefore analyzed serum sam-
ples from an independent, additional cohort of 33 patients (termed 
Marburg cohort) in whom posttreatment samples were taken 3–5 
weeks following the last infusion of IVIG (mean ± SD: 4 ± 0.6) and 
in which total serum IgG levels after IVIG therapy were unchanged 
compared with pretreatment samples (Supplemental Figure 5B). In 
this cohort, reduction in clinical disease severity scores upon IVIG 
therapy was significantly associated with an induction of IgG Fc 
sialylation (r = 0.63, P = 0.0001) (Figure 7B). We consider it unlikely 
that we profiled the sialic acid content of the IVIG product used to 
treat these patients, since the correlation of Inflammatory Neuropa-
thy Cause and Treatment (INCAT) disease score reduction with 
increased IgG Fc sialylation remained significant after exclusion of 
3 patients who showed substantially increased IgG levels 3–5 weeks 
after IVIG therapy as compared with pretreatment levels (r = 0.57, 
increased binding of C1q, and the presence of sialic acid abrogated 
increased C1q binding of galactosylated Fc fragments (Figure 6B). 
These data indicate that Fc sialylation exerts immunoregulatory 
functions through inhibition of C1q binding and activation of the 
classical complement pathway, leading to reduced complement-
mediated cytotoxicity.
IgG Fc sialylation is associated with autoimmune disease remis-
sion. To address the clinical significance of our findings, we investi-
gated whether IgG Fc sialylation is associated with disease activity in 
patients with chronic inflammatory demyelinating polyneuropathy 
(CIDP), the most common chronic autoimmune neuropathy (25). 
Humoral immune responses are considered to have a crucial role in 
mediating peripheral nerve damage in CIDP (26, 27). Complement 
component 3d is deposited on the outer surface of Schwann cells and 
the compact myelin in biopsies from patients with CIDP (28, 29). Sera 
and IgG antibodies from CIDP patients induce peripheral demyelin-
ation in host animals (30), can increase the permeability of the blood-
nerve barrier, and impair nerve conduction in various models of 
peripheral neuropathies (27). Moreover, removal of humoral immune 
mediators by plasma exchange is associated with short-term clinical 
disease remission and first-line therapy in CIDP (31, 32).
First, we analyzed 19 patients with CIDP who were included in 
a randomized placebo-controlled clinical trial testing the efficacy of 
i.v. injection of 10% caprylate-chromatography–purified IVIG — 2 g/
kg body weight initially and 1 g/kg body weight every 3 weeks there-
after for 24 weeks — compared with 0.1% albumin (placebo) (32). In 
Figure 3. Cell-surface antigen expression on target cells and antigen binding properties of antibody glycovariants. (A) Raji and Ramos cells were ana-
lyzed for CD20 expression by flow cytometry. Gray histograms, unstained cells; open histograms, stained cells. (B) MO3.13 cells lentivirally transduced to 
express human MOG were analyzed for MOG expression by flow cytometry. Gray histograms, unstained cells; open histograms, stained cells. CD20+ Raji 
cells were incubated with RTX or glycovariants of RTX (C) and MO3.13 MOG cells with hu8-18C5 (anti-MOG) or glycovariants of hu8-18C5 (D) following incu-
bation with a fluorescently labeled anti-Ig antibody and detection of antibody binding by flow cytometry. MFI, median fluorescence intensity.
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We profiled total serum IgG Fc glycovariants since no specific 
pathogenic autoantibody or single triggering antigen has yet been 
identified in CIDP (34). Thus, while our data do not demonstrate 
induction of sialylation in specific autoantibodies causing the dis-
ease, they indicate that induction of Fc sialylation in CIDP sera is 
associated with clinical disease remission.
The observed mechanism of action of Fc sialylation was not 
identified in animal models of autoimmune diseases in which 
IVIG therapy and Fc sialylation proved to be effective, such as the 
K/BxN serum transfer arthritis model and the antiplatelet mono-
clonal antibody 6A6–mediated model for immune thrombocyto-
penia (10, 11, 13, 20). However, the aforementioned autoimmune 
disease models are largely mediated by IgG-dependent activation 
of innate immune effector cells via crosslinking of cellular FcγRs, 
whereas IgG-dependent activation of the classical complement 
pathway via C1q was shown to be largely dispensable for disease 
development (1, 24, 35–49).
The N-glycan resides in the CH2 domain, which is required for 
C1q binding (50). For human IgG1, 4 spatially close sites on the sur-
face of the antibody — D270, K322, P329, and P331 — were shown 
to constitute the C1q binding epicenter (51). However, most of the 
aforementioned sites are conserved in human IgG isotypes that 
are deficient in C1q binding; it has therefore been suggested that 
the composition of the N-glycan might be critical for the antibod-
ies’ conformation and its ability to bind C1q (51, 52). In line with 
this assumption, we observed that presence of terminal galactose 
increases binding affinities for C1q and that subsequent addition 
of sialic acid inhibited the increased C1q binding. Crystallographic 
and biophysical studies on sialylated and asialylated IgG Fc frag-
ments have shown that IgG Fc sialylation disrupts glycan inter-
actions with amino acid residues of the CH2 domain, leading to 
significant conformational changes seen in the protein structure 
P = 0.0011). Moreover, Fc-sialylated glycoforms represent only a 
minor fraction of glycovariants present in IVIG products (6), and 
the increase of total IgG serum levels 2 weeks after the last infusion 
in the first cohort of patients in remission was not associated with 
an upregulation of Fc sialylation (Supplemental Figure 5C). No sig-
nificant correlation was observed for IgG Fc galactosylation, fucosyl-
ation, and the reduction of disease severity (Figure 7B).
We additionally determined complement activation in patients 
with CIDP from whom additional serum samples were available 
(Marburg cohort). Levels of soluble terminal complement complex 
(TCC, SC5b-9) generated by the assembly of C5b through C9 and 
previously shown to correlate with disease activity in patients with 
SLE (33) were quantified by ELISA according to the manufacturer’s 
recommendation. CIDP patients with high levels of Fc–sialic acid 
induction — as defined by at least 2-fold induction of Fc sialylation 
— showed significantly lower levels of complement activation fol-
lowing IVIG therapy compared with baseline levels (Figure 7C). 
Thus, induction of Fc sialylation is associated with both spontane-
ous and treatment-induced disease remission, as well as decreased 
levels of TCC formation.
Discussion
Complement activation is a potent proinflammatory mechanism 
by which IgG antibodies trigger immune responses during infec-
tion, and its deregulation causes tissue damage in a wide array of 
human inflammatory, degenerative, and autoimmune diseases 
(23). Our study shows that the antiinflammatory activities of 
sialylated IgG Fc include the impairment of complement-depen-
dent cytotoxicity by reducing the binding affinity of IgG Fc to C1q. 
Induction of IgG Fc sialylation is associated with clinical disease 
remission in CIDP, an autoimmune disease in which humoral 
immune responses are central in mediating tissue damage.
Figure 4. SPR of C1q binding to RTX and tetra-Fc–sialylated RTX. Sensorgrams and results of global fits (table) from SPR measurements.
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(53, 54). These data suggest that addition of 
sialic acid induces structural changes in IgG 
Fc fragments, which translate into reduced 
C1q binding and CDC.
Taken together, we identified an FcγR-
independent mechanism by which Fc-
sialylated glycovariants acquire antiinflam-
matory properties and limit proinflammatory 
IgG effector function. This mechanism might 
complement immunomodulatory effects of 
sialylated IgG associated with upregulation 
of the inhibitory FcγRIIB (1, 55) and supports 
the development of strategies that target 
increased Fc sialylation for the treatment of 
human autoimmune diseases (56).
Methods
Patients. Samples and clinical data were col-
lected during a randomized placebo-controlled 
trial (ICE trial) testing the efficacy of i.v. injec-
tion of 10% caprylate-chromatography puri-
fied immunoglobulin (IGIV-C, Gamunex, Gri-
fols Therapeutics Inc.) in patients with CIDP 
(32). Patients included in the ICE trial did not 
receive IVIG treatment in the 3 months before 
study entry. An additional cohort of patients 
was recruited between 2010 and 2013 at the 
Department of Neurology, University of Mar-
burg, Germany (Supplemental Table 1). All 
patients fulfilled the European Federation of 
Neurological Societies/Peripheral Nerve Soci-
Figure 5. C1q binding to IgG Fc glycovariants. 
(A) Lectin immunoblotting of RTX glycovariants. 
(mannose: LCA; terminal galactose: ECL; sialic acid: 
SNA). (B) Time-course of C1q binding to CD20+ Raji 
cells in the presence or absence of differentially 
glycosylated RTX. Mean ± SD of 6 independent 
experiments. Median fluorescence intensity 
obtained for the unmodified antibody after 60 
minutes was set to 100, and the relative signals 
were calculated. (C) Quantification of RTX antibody 
glycovariant-dependent C1q binding to CD20+ Raji 
and Ramos cells after 30 minutes incubation. 
Mean ± SD of at least 3 independent experiments. 
Statistics were performed by 1-way ANOVA and 
Bonferroni post test. (D) Lectin immunoblotting 
of hu8-18C5 (anti-MOG) glycovariants. (E) Time-
course of C1q binding to MO3.13 MOG cells in the 
presence or absence of differentially glycosylated 
variants of hu8-18C5. Mean ± SD of 8 indepen-
dent experiments. Median fluorescence intensity 
obtained for the unmodified antibody after 30 
minutes was set to 100 and the relative signals 
were calculated. (F) Quantification of hu8-18C5 
antibody glycovariant–dependent C1q binding to 
MO3.13 MOG cells after 60 minutes. Statistics were 
performed by 1-way ANOVA and Bonferroni post 
test. (G) Representative flow cytometry stainings 
showing C1q binding to the indicated cell type and 
antibody after 1 hour incubation.
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ety diagnostic criteria for CIDP. They were prospectively followed 
during IVIG therapy using the INCAT score to monitor clinical treat-
ment response. Patients did not receive IVIG therapy before study 
entry. Serum samples were collected at each visit.
Buffers and reagents. RPMI-1640, DMEM, penicillin-streptomy-
cin (P/S), pooled human serum, TO-PRO-3 Stain, LIVE/DEAD Fix-
able Near-IR Dead Cell Stain Kit, LIVE/DEAD Fixable Aqua Dead 
Cell Stain Kit, 1-Step Ultra TMB-ELISA Substrate Solution and 
CaptureSelect IgG-CH1 PRO Affinity Matrix were purchased from 
Invitrogen. Recombinant human IL-2 was purchased from Pepro-
Tech. PKH26 Red Fluorescent Cell Linker Kit was purchased from 
Sigma-Aldrich. Ficoll-Paque was purchased from GE Healthcare. 
Accutase was purchased from StemCell Technologies Inc. MACS 
NK Cell Isolation Kit-II (negative selection) and B Cell Isolation 
Kit (CD19+ selection) were purchased from Miltenyi Biotec. Human 
serum complement, C5 depleted human serum, MicroVue SC5b-9 
Plus ELISA, and recombinant human C1q were purchased from 
TECOmedical Group. EZ-Link NHS-PEG12-Biotin was purchased 
from Thermo Scientific. Papain and Nutridoma-SP were purchased 
from Roche Applied Science. HiLoad 16/60 Superdex 200 column, 
HiTrap Protein G HP Columns, StrepTrap HP Columns, HisTrap HP 
columns, and Protein G Sepharose 4 Fast Flow were purchased from 
GE Healthcare. Ceramic Fluoroapatite (CFT-II, 40 μM) was pur-
chased from Bio-Rad. Biotinylated lectins (Lens culinaris agglutinin 
[LCA], Sambucus nigra agglutinin [SNA], Erythrina cristagalli lectin 
[ECL], and Aleuria aurantia lectin [AAL]) and SNA-Agarose were 
purchased from Vector Laboratories. Neuraminidase was purchased 
from New England Biolabs Inc. UDP-Galactose, CMP-Sialic Acid, 
β1,4-Galactosidase were purchased from Merck. StarGate cloning 
and expression system was purchased from IBA. CMD500L sensor 
chip was from Xantec.
Antibodies and streptavidin. RTX (MabThera, catalog 10129436) 
was purchased from Roche Applied Science. Monoclonal mouse 
anti–human C1q (catalog A201), biotinylated anti–human C1q (cata-
log A700), and anti–human-C3c (catalog A701) were purchased from 
TECOmedical Group. Anti–human IgG Fc-HRP (catalog A0170) was 
purchased from Sigma-Aldrich. Anti–CD20-PE-Cy7 (clone 2H7) was 
purchased from eBioscience. Polyclonal rabbit anti–mouse IgG (H+L)-
Alexa Fluor 488 (catalog A-11059) was purchased from Invitrogen. 
Streptavidin-FITC (catalog 405202) and streptavidin-PE (catalog 
405204) were purchased from BioLegend.
CDC assay. Raji or Ramos cells expressing the target anti-
gen of RTX (CD20; Figure 3A) were used to assess RTX-mediated 
CDC. Therefore, 7 × 104 cells were placed in a humidified incuba-
tor at 37°C and 5% CO2 in RPMI-1640 containing P/S (50 U/ml) in 
96-well V-bottom plates in the presence or absence of RTX or gly-
covariants of it. After 30 minutes, human serum complement was 
added to a final concentration of 5%, and the incubation was con-
tinued for 12 hours. For hu8-18C5–mediated CDC, 2 × 104 MO3.13 
MOG cells were seeded in 96-well flat-bottom plates in DMEM plus 
10% FCS. On the next day, the medium was removed, and DMEM 
containing 15% serum complement with or without hu8-18C5 or a 
glycovariant of it was added following incubation for 4 hours in a 
humidified incubator at 37°C and 5% CO2. For cell-death assess-
ment, TO-PRO-3 stain was added to a final concentration of 200 
nM. Cells were acquired using BD FACS Canto-II (BD Biosciences) 
and analyzed with FlowJo (Tree Star).
ADCC assay. ADCC assay was performed as previously described 
(57). Human peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats using Ficoll-Paque. NK cells were negatively 
selected using MACS NK cell isolation kit, and B cells were positively 
selected using MACS CD19+ selection kit. Both cells were cultured 
overnight in RPMI supplemented with P/S (50 U/ml) and 5% heat-
inactivated pooled human serum in 24-well plates at 5 × 106 cells per 
well. NK cell medium was additionally supplemented with 100 IU 
IL-2. On the next day, B cells were stained with PKH26 according to 
the manufacturer’s recommendation. B cells (1 × 104) were incubated 
in the presence of autologous NK cells (1 × 103–1 × 105) and RTX (0.1 
μg/ml–1 ng/ml) in RPMI supplemented with P/S (50 U/ml), 5% heat-
inactivated pooled human serum, and 100 IU IL-2 in 96-well round-
bottom plates for 18 hours in a humidified incubator at 37°C and 5% 
CO2. For cell-death assessment, TO-PRO-3 stain was added to a final 
concentration of 200 nM. Cells were acquired using BD FACS Can-
to-II and analyzed with FlowJo.
Figure 6. C1q binding to human poly-
clonal IgG Fc glycovariants. (A) Lectin 
immunoblotting of Fc purified from 
human polyclonal IgG and enriched for 
sialylated Fc or desialylated (mannose: 
LCA; terminal galactose: ECL; sialic acid: 
SNA). (B) C1q binding to polyclonal IgG Fc 
glycovariants measured by ELISA. Mean 
and ± SEM of 3 independent experi-
ments. C1q binding was normalized to 
unmodified Fc at 10% serum. Individual 
curves were compared with Fc using 
2-way ANOVA and Bonferroni post test 
comparing Fc and desialylated Fc, or 
Fc and sialic acid–enriched Fc (P values 
below curve).
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hu8-18C5 was purified by cotransfecting the calcium phosphate 
precipitated expression vectors in HKB-11 cells. After 12 hours, 
the medium was exchanged to DMEM containing P/S (50 U/ml) 
and 1% Nutridoma-SP. The culture supernatant was harvested 4 
days later, and antibodies were purified using HiTrap Protein G HP 
columns according to the manufacturer’s instructions using GE 
Aekta prime plus.
Purification of recombinant glycosyltransferases. For purification 
of sialyl- and galactosyl-transferases, cDNA of bovine β1,4GalT and 
human ST6Gal1 was cloned into pCSG-IBA-144 expression vectors 
using the StarGate cloning system (IBA) according to the manufactur-
er’s instructions. This yields plasmids encoding for proteins contain-
ing an N-terminal Twin-Strep-tag and a C-terminal Hexahistidine-
tag. 293T cells were cultured under standard cell-culture conditions in 
DMEM containing 10% FCS and P/S (50 U/ml) and transfected with 
calcium-phosphate precipitated plasmids encoding either β1,4GalT or 
ST6Gal1. After 12 hours, the medium was replaced with fresh DMEM 
containing 10% FCS and P/S (50 U/ml), and cells were cultured for 
another 3 days. The cell supernatant was harvested, and the proteins 
were purified by immobilized metal ion affinity chromatography (His-
Trap HP columns) and subsequently Strep-Tactin affinity chroma-
tography (Strep-Trap HP columns) according to the manufacturer’s 
instructions using GE Aekta prime plus.
Generation of antibody glycovariants. Tetra-Fc–sialylated RTX 
was generated by chemoenzymatic glycoengineering as previously 
described (17) with adequate modifications. Briefly, commercial 
RTX (8 mg) was incubated with EndoS WT (25 μg) at 37°C for 1 
hour, and the completion of deglycosylation was confirmed by 
LC/MS analysis. The deglycosylated antibody was purified using 
a HiTrap protein A column, and the eluted fractions were con-
centrated and buffer exchanged into 1 × PBS pH 7.4. The purified 
Fuc-α1,6-GlcNAc-RTX (7 mg) and sialylated complex type oxazo-
line (3.5 mg) were incubated with EndoS D233Q (175 μg) at 37°C in 
100 mM Tris pH 7.4 (500 μl total volume). The reaction progress 
was monitored using LC/MS analysis, and complete transfer was 
FcγR binding assay. RTX and tetra-Fc–sialylated RTX were bioti-
nylated using EZ-Link NHS-PEG12-Biotin according to the manufac-
turer’s recommendations. CHO cells (1 × 105) stably expressing none 
or 1 of the human FcγRs (58), a gift from Falk Nimmerjahn (Depart-
ment of Biology, University of Erlangen-Nuremberg, Germany), were 
incubated for 30 minutes on ice in the presence of RTX or tetra-Fc–
sialylated RTX. Cells were washed twice with PBS and incubated for 
30 minutes with streptavidin-FITC for detection of binding and LIVE/
DEAD Fixable Near-IR Dead Cell Stain Kit for dead cell exclusion. 
After washing twice with PBS, cells were acquired using BD FACS 
Canto-II and analyzed with FlowJo.
Purification of Fc, desialylated Fc, and sialic acid–enriched Fc from 
polyclonal IgG. IVIG (Pivigen, CSL Behring) was used as source of 
human IgG. IgG (550 mg) was incubated in 0.02 M EDTA and 0.02 
M L-cysteine in PBS at pH 6.5 with 0.8 mg papain for 2 hours at 25°C. 
Uncut IgG and papain were separated by size exclusion with a HiLoad 
16/60 Superdex 200 column and GE Aekta purifier. The fraction con-
taining the Fc and Fab fragments was concentrated and dialyzed to 
5 mM Na-phosphate buffer pH 7.1. Fab and Fc were separated using 
a Ceramic Fluoroapatite column (CFT-II, 40 μm), which binds Fab 
but not Fc. For purification of sialic acid–enriched Fc, Fc was dialyzed 
to TBS and CaCl2 was added to a final concentration of 0.1 M. Sialic 
acid–enriched Fc was purified from 40 mg Fc by binding to 4 ml SNA-
Agarose and elution with 0.5 M lactose in TBS as previously described 
(11). For neuraminidase treatment, Fc was dialyzed to 50 mM sodium 
citrate pH 6 and incubated with 1 unit neuraminidase per μg Fc for 
48 hours at 37°C. Neuraminidase was removed using Protein-G sep-
harose 4 Fast Flow. For further purification, Fc, desialylated Fc, and 
sialic acid–enriched Fc were cleared from residual Fab using a Cap-
tureSelect IgG-CH1 pro affinity matrix and reapplied to a HiLoad 
16/60 Superdex 200 column.
Purification of hu8-18C5 antibody. The hu8-18C5 antibody has 
been generated by cloning of the 8-18C5 hybridoma–derived Igh 
and Igk variable–region sequences into human IgG1 heavy-chain 
and κ light chain expression vectors as previously described (21). 
Figure 7. Induction of IgG Fc sialylation is associated with disease remission in CIDP. (A) Serum IgG Fc glycan composition of CIDP patients analyzed 
by lectin blotting. Relative IgG Fc glycan abundance of CIDP patients before and after a 24-week observation period. Patients undergoing spontaneous 
disease remission are compared with those with stable or worsening disease (no remission). Statistics were performed by Mann-Whitney U test. (B) IgG 
Fc glycan composition analysis of CIDP patients (Marburg patient cohort) before and 3–5 weeks after receiving the last IVIG injection. Fold changes in 
glycan composition are compared with disease activity changes reflected by the INCAT score. Statistics were performed by Spearman test. (C) Complement 
activation as defined by serum levels of the TCC (SC5b-9) quantified by ELISA before and 3–5 weeks after IVIG therapy (Marburg patient cohort). Statistics 
were performed by Mann–Whitney U test.
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complement diluted in PBS containing 0.05% Tween20 (PBS-T) and 
1% BSA for 2 hours at room temperature. After washing with PBS-T, 
wells were incubated for 1 hour with biotinylated anti-C1q, washed 
with PBS-T, and incubated for 1 hour with streptavidin-HRP. HRP 
activity was quantified using incubation TMB-ELISA substrate and 
colorimetric detection at 450 nm.
Serum IgG quantification. Serum samples were taken before the 
initiation of the study (baseline) and 24 weeks (ICE trial) or >7 weeks 
(Marburg cohort) thereafter; samples were stored at –80°C. Total 
serum IgG levels were determined using a commercially available 
human IgG ELISA (Immundiagnostik).
Lectin immunoblotting and Fc-linked glycan profiling. Fc-linked gly-
cans were analyzed by lectin immunoblotting using the biotinylated 
lectins SNA, ECL, LCA, and AAL (10, 11). Lectin binding was detected 
using HRP-labeled streptavidin and quantified by chemiluminescence 
using ImageJ. Signal intensities for each glycan (fucose, terminal 
galactose, and sialic acid) were normalized to the signal obtained for 
the core glycan (mannose).
SC5b-9 ELISA. Complement activation was determined in 
patients with CIDP from whom additional serum samples were avail-
able (Marburg cohort) using an ELISA detecting serum levels of the 
TCC (SC5b-9) according to the manufacturer’s recommendation.
SPR. A Biacore T100 (GE Healthcare) was used for measuring 
kinetic data. Antibodies were immobilized on a CMD500L sensor 
chip surface via EDC/ NHS (0.4 M/ 0.1 M) surface activation in 10 
mM acetate buffer pH 5.5 at 0.1 mg/ml (2,800/2,800 RU for RTX/
tetra-Fc–sialylated RTX) as previously described (59). Dilution series 
of C1q (5 nM–20 pM) were injected for 75 seconds at 30 μl/min. Sen-
sograms were analyzed using Biacore Evaluation Software applying 
a 1:1 kinetic model.
Statistics. All data represent the mean ± SD. Statistical significance 
was defined at a P value of 0.05 or less. All analyses were performed 
using Prism software, version 5 (GraphPad Software, Inc.). Specific 
statistical tests are listed in figure legends.
Study approval. The IRBs and ethics committees of the University 
of Marburg (file reference: 46/00) and all centers that participated 
in the ICE trial (32) approved the study. All patients provided written 
informed consent.
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achieved in 1.5 hours. The tetra-Fc–sialylated RTX was purified 
using a HiTrap protein A column and was concentrated and buffer 
exchanged into 1 × PBS pH 7.4. LC/MS: heavy chain of RTX with 
sialylated complex type glycan, M = 51412 Da; found (m/z), 51412 
(deconvolution data). Enzymatic galactosylation and sialylation 
were performed as previously described (11, 19). For galactosyl-
ation, antibodies were buffer-exchanged to 0.2 mM MES pH 6.5 
and incubated for 24 hours at 37°C in the presence of 5 μg β1,4GalT 
per mg antibody, 10 mM UDP-galactose, and 20 mM MnCl2. Non-
galactosylated antibodies (unmodified) were treated the same 
way but without the addition of UDP-galactose and β1,4GalT. 
After buffer exchange to 25 mM MOPS 100 mM KCl (pH 7.2), Fc-
galactosylated antibodies were Fc-sialylated by the addition of 50 
μg ST6Gal1 per mg antibody and CMP-sialic acid at a final con-
centration of 1.5 mM. The reaction was incubated for 24 hours at 
37°C. Nonsialylated antibodies (unmodified and galactosylated) 
were treated the same way but without the addition of CMP-sialic 
acid and ST6Gal1. All antibodies were buffer-exchanged to TBS. 
To enrich for antibodies containing sialic acid, SNA lectin affinity 
chromatography was performed as previously described (11). For 
degalactosylation, RTX or hu8-18C5 was dialyzed to 50 mM sodi-
um phosphate pH 6.0 and incubated 6 hours at room temperature 
and 1 hour at 37°C in the presence of 30 mU β1,4-galactosidase per 
mg antibody. Finally, all antibodies were purified using protein-G 
sepharose 4 fast flow according to the manufacturer’s instruction, 
dialyzed to PBS, and sterilized by 0.2 μM filtration. Acrylamide 
gel electrophoresis and silver staining were performed to test anti-
body integrity and purity, and lectin-blotting was used to confirm 
glycan modifications.
C1q binding assay. For C1q binding to Raji or Ramos cells, 2 × 105 
cells were seeded in RPMI-1640 containing 1% C5-depleted human 
serum in the presence of 10 μg/ml RTX or RTX glycovariants for 
5, 15, 30, 60, or 120 minutes in a humidified incubator at 37°C and 
5% CO2. For C1q binding to MO3.13 MOG cells, cells were detached 
using accutase, and 1 × 105 cells were seeded in DMEM containing 
1% C5-depleted serum in the presence of 2.5 μg hu8-18C5 or hu8-
18C5 glycovariants for 5, 15, 30, 60, or 120 minutes in a humidified 
incubator at 37°C and 5% CO2. C1q binding was detected by stain-
ing on ice with biotinylated anti-C1q for 1 hour. Cells were washed 
twice with PBS and incubated on ice with streptavidin-PE and LIVE/
DEAD Fixable Aqua Dead Cell Stain Kit for 25 minutes. After wash-
ing twice with PBS, samples were acquired using BD FACS Canto-II 
and analyzed with FlowJo.
C3b deposition assay. Raji cells (2 × 105) were seeded in RPMI-1640 
containing 1% C5-depleted serum in the presence of 10 μg/ml RTX 
or RTX glycovariants for 5, 15, 30, 60, or 120 minutes in a humidified 
incubator at 37°C and 5% CO2. For C3 deposition assessment, cells 
were stained with biotinylated anti-C3c for 1 hour on ice. Cells were 
washed twice with PBS and incubated on ice with streptavidin-PE and 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 25 minutes. After 
washing twice with PBS, samples were acquired using BD FACS Can-
to-II and analyzed with FlowJo.
C1q binding ELISA. Microtiter plates were coated overnight 
at 4°C with 0.5 μg Fc, desialylated Fc, or sialic acid–enriched Fc in 
coating buffer (0.05 M sodium carbonate buffer, pH 9). Binding 
efficiency to the plate was examined using anti–human IgG Fc-HRP 
as the probe. Wells were washed and incubated with human serum 
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